Publicação
Polysaccharide of Escherichia coli in the Prevention of Recurrent Urinary Tract Infection: An Evidence-Based Review
| Resumo: | Introduction: Recurrent urinary tract infection is frequent and it is related to morbidity, costs and growing antibiotic resistance. OM 8930 vaccine is composed by Escherichia coli polysaccharide and it is a possible prophylactic measure, but there is doubt as to its effectiveness.Material and Methods: We performed a systematic review in evidence-based medicine databases with rigorous bibliography selection.Results: We found an effective decrease of recurrences in test groups.Discussion: We recommend the administration of the vaccine as prophylaxis of recurrent cystitis.Conclusion: The vaccine has impact on the recurrent cystitis relapse rate. We suggest that more studies be carried out to evaluate the vaccine cost-benefit and its effectiveness in complicated urinary infections. |
|---|---|
| Autores principais: | Tinoco, Manuel |
| Outros Autores: | Santos, Mélody; Reitor, Conceição; Rodrigues, Andreia; Monteiro, João |
| Assunto: | Adjuvants Immunologic/therapeutic use Escherichia coli Infections Urinary Tract Infections Uropathogenic Escherichia coli Adjuvantes Imunológicos/uso terapêutico Escherichia coli Uropatogénica Infecções por Escherichia coli Infecções Urinárias |
| Ano: | 2018 |
| País: | Portugal |
| Tipo de documento: | artigo |
| Tipo de acesso: | unknown |
| Instituição associada: | Ordem dos Médicos |
| Idioma: | português |
| Origem: | Acta Médica Portuguesa |
| Resumo: | Introduction: Recurrent urinary tract infection is frequent and it is related to morbidity, costs and growing antibiotic resistance. OM 8930 vaccine is composed by Escherichia coli polysaccharide and it is a possible prophylactic measure, but there is doubt as to its effectiveness.Material and Methods: We performed a systematic review in evidence-based medicine databases with rigorous bibliography selection.Results: We found an effective decrease of recurrences in test groups.Discussion: We recommend the administration of the vaccine as prophylaxis of recurrent cystitis.Conclusion: The vaccine has impact on the recurrent cystitis relapse rate. We suggest that more studies be carried out to evaluate the vaccine cost-benefit and its effectiveness in complicated urinary infections. |
|---|